Yikang Jucheng Files IPO Prospectus to Build an Integrated Ecosystem of Touch-Based Glucose Monitoring, Platform Services, and AI-Assisted Diagnosis

It is beyond doubt that blood glucose monitors have remained at the forefront of industry attention in recent years.

On one hand, diabetes not only poses a serious threat to human life and health (prolonged hyperglycemia can cause multi-organ damage to the eyes, kidneys, cardiovascular system, and other tissues, inducing more than 100 types of complications such as cardiovascular disease, nephropathy, retinopathy, neuropathy, and diabetic foot, which can be life-threatening in severe cases), but also imposes significant psychological stress and medical burdens on patients and their families.

Regrettably, China is the country with the largest number of diabetes patients worldwide. According to data from the International Diabetes Federation (IDF), the global number of people with diabetes is projected to reach 608 million by 2030, with China’s diabetic population estimated at 143 million, accounting for 23% of the global total and making it the country with the highest number of diabetes cases.

On the other hand, regular self-monitoring of blood glucose facilitates the management and treatment of diabetes and effectively reduces the risk of complications. Moreover, for at-risk populations and healthy individuals not yet diagnosed with diabetes, routine blood glucose monitoring can effectively prevent and control the onset and progression of the disease, thereby lowering the risk of developing diabetes.

Regrettably, despite China’s economic boom, rising public health awareness, and strong policy support recognizing the importance of diabetes prevention and control, diabetes management in the country still exhibits the “three lows”: low diagnosis rate, low treatment rate, and low penetration of blood glucose monitoring.

However, when the high severity of the disease, the large patient population, low market penetration, and strong national policy support converge, these industry characteristics collectively underscore the immense growth potential of blood glucose monitoring.

Among these, some companies have chosen to focus on BGM (blood glucose monitoring via fingerstick testing), while others have prioritized CGM (continuous glucose monitoring). These two glucose monitoring methods are often compared, with high expectations placed on the future development of CGM. However, in recent years, a third approach has emerged alongside them: TGM (touch-based glucose monitoring).

Compared with the invasiveness, pain, inconvenience of carrying, and inability to accurately present blood glucose fluctuations associated with BGM, and the minimal invasiveness, allergy risks, and high cost of CGM,TGM touch-screen blood glucose meters are characterized by their non-invasive nature and high patient compliance. Thanks to the efforts of domestic enterprises, technological breakthroughs have been achieved, and the accuracy of blood glucose testing now meets the requirements for daily monitoring and health management.

Currently, both domestic and international companies are engaged in the research, development, and production of non-invasive blood glucose meters, with Shenzhen Yikang Jucheng Biomedical Technology Co., Ltd. (hereinafter referred to as "Yikang Jucheng") being one of them.

Yikang Jucheng is dedicated to the research and development, manufacturing, and sales of smart medical devices, as well as providing “product + service” solutions based on an internet cloud-enabled proactive health management platform. Its portfolio includes technology enterprises such as Yikang Anjia, Dongguan Yushuo, and Beijing Jiaheshan. Notably, Yikang Anjia has been engaged in research and exploration in the field of TGM touch-screen blood glucose meters for nearly a decade. Its team comprises elites from mainland Chinese universities and Taiwan’s semiconductor technology sector, along with overseas life science experts. Their professional expertise spans industrial design, semiconductor integrated circuits, sensors, electronic engineering, mathematical algorithms, and traditional Chinese medicine healthcare.

TGM Touchscreen Blood Glucose Meter is the core product line of Yikang Jucheng Technology.

Non-invasive, consumable-free, self-calibrating, and multi-functional are the main features of this product.Leveraging technical principles such as advanced composite high-precision sensors and control chip technology, spectroscopy, impedance spectroscopy, metabolic heat method, PPG+ECG integration, and secondary neuron algorithms, Yikang Jucheng Technology has successfully developed a product capable of measuring blood glucose levels through mere “touch.”

Moreover, each test is rapid (delivering results directly in just one minute), and its precision and accuracy have been verified and certified by relevant national professional institutions.

Experimental results provided by Yikang Jucheng indicate that the precision and accuracy of its touch-screen blood glucose meter meet the national standards for blood glucose meters. Compared with fingertip blood glucose meters, more than 95% of the detected blood glucose data fell within Zones A and B. (Note: According to co-founder Cheng Yilang, this conclusion was drawn by analyzing the distribution of paired points comparing glucose concentrations measured by the test medical device against venous plasma glucose concentrations across Zones A, B, C, D, and E. Zone A represents clinically absolute accuracy; Zone B represents clinically acceptable accuracy; while Zones C, D, and E are considered inaccurate.) Furthermore, in self-monitoring of blood glucose for patients with type 2 diabetes, its accuracy meets the requirements for home monitoring and health management.

Moreover, the product features an autonomous calibration function that automatically calibrates through testing with a minimally invasive blood glucose meter, making it suitable for patients in various conditions.

The product can also be integrated into smart devices or intelligent scenarios to build an IoT-based health ecosystem service system. By combining information on patients’ daily diet, exercise, and medication, it provides comprehensive blood glucose management and health management services for individuals with diabetes and those in a sub-health state.

Currently, the product has obtained CE, FCC, and RoHS international certifications, and has been awarded the Most Valuable Award at the 4th Global IoT Conference and the Global Smart Health & Elderly Care Technology Innovation Summit, as well as the First Prize in the Sports and Health Industry Category of the 9th China Innovation and Entrepreneurship Competition.

Interestingly, behind this “versatile” product is an equally “versatile” team—comprising members with backgrounds in semiconductor integrated circuits, sensors, micro-electromechanical systems (MEMS), electronic engineering, industrial design, polymer materials for medical devices, and system integration, as well as those with expertise in image processing, mathematical algorithms, and traditional Chinese medicine (TCM) healthcare. As founder Cheng Yilang put it, “We have crossed nearly seven disciplinary boundaries.”

For example, Dai Ruichi, Founder and Chairman, has over 20 years of experience in the semiconductor chip design industry. Cheng Yilang, Founder and President, graduated with a major in Polymer Materials from the Department of Mechanical Engineering at Beijing University of Chemical Technology and possesses 15 years of operational management experience in the commercialization of scientific and technological achievements. Liu Wei, Head of Product Planning and Technology Development, graduated with a degree in Electronic Engineering from Tsinghua University, previously served as a Director of the China Health Care Association, and has 20 years of experience leading original product design, R&D, and mass production services. Ouyang Jianxiang, Head of Market Planning and Marketing, graduated with a degree in Clinical Medicine and has many years of experience in pharmaceutical and medical device sales, demonstrating a profound understanding and extensive accumulation of expertise in China’s pharmaceutical and medical device markets.

“Our core team’s professional backgrounds and industry experience are highly complementary, which is critical to the development and commercialization of our blood glucose monitor,” said Cheng Yilang.

Furthermore, building on this multidisciplinary team foundation, Cheng Yilang revealed that the development of Yikang Jucheng’s touch-screen blood glucose meter also received support from domestic universities, hospitals at various levels, and overseas teams—resources that constitute Yikang Jucheng’s accumulated competitive advantage.

Moreover, in Cheng Yilang’s attribution, the consumer-needs-centered R&D philosophy is also one of the key reasons why Yikang Jucheng achieved breakthroughs in the development of touch-screen blood glucose meters.

Specifically, Yikang Jucheng’s R&D philosophy is customer-centric, grounded in market research, driven by technological integration, and supported by large-scale production. It is committed to original development and design, with the aim of providing intelligent medical health monitoring devices and smart health management services that are user-friendly, differentiated, cost-effective, practical, environmentally friendly, competitive, and aligned with industry trends.

“Frankly speaking, many core members of our R&D team, myself included, have backgrounds in industrial design. Industrial design is not merely about aesthetics; it is a user-centric approach to design. Therefore, Yikang Jucheng’s design philosophy has been inherently geared toward meeting users’ practical needs from its very inception. All of our research and development efforts are driven by the exploration of both users’ existing and latent needs,” said Cheng Yilang sincerely.

And this, which came into being only through the combined efforts of multiple factors and stakeholders,Touch-sensitiveBlood glucose monitors are, in fact, just one component of Yikang Jucheng Technology’s business model.

“We are not merely delivering a single product; what we aim to deliver is a closed-loop service model.” During the interview, Cheng Yilang emphasized this point repeatedly.

As depicted by Cheng Yilang,Based on the TGM touch-screen blood glucose monitor, Yikang Jucheng has established a tripartite business model.

Among these, the touch-screen blood glucose monitor serves solely as a detection tool. After testing, users can query their results via Yikang Jucheng’s service platform. If abnormal results are detected, the system automatically issues alerts and warnings and generates corresponding intervention plans, thereby establishing a closed-loop service that integrates testing, health management platform services (i.e., alerts and warnings), and assisted diagnosis and treatment.

Within this closed loop,Yikang Jucheng will not only seek partners such as hospitals and pharmacies through a regional agency model, but also engage clinics, community health services, and home-based elderly care enterprises via an urban partnership model.

The so-called "Urban Partner" system was proposed by Yikang Jucheng based on the regional characteristics of China's healthcare and medical industry, primarily targeting local institutions or enterprises that possess medical service qualifications and capabilities.

Not only that,In the future, Yikang Jucheng’s platform services will become more tangible, integrating not only pharmacies and AI-powered Traditional Chinese Medicine (TCM) services but also expanding into home-based nursing care.“Because our goal is to ensure that services are effectively implemented within communities and families.”

“Currently, the diabetes prevention and control sector, as well as the broader chronic disease management industry, face two major challenges: first, the health concepts of chronic disease prevention and ‘preventive treatment’ (treating potential diseases before they manifest) require continued promotion and deeper adoption by the government and various industry stakeholders; second, new products and service models inevitably encounter difficulties during the initial stages of market rollout, requiring time for both the industry and users to adapt and accept them. Addressing these challenges demands concerted efforts from all parties across the industry,” stated Cheng Yilang.

“However, the introduction of the Outline of the Healthy China 2030 Plan has clearly mandated the integration of the concept of ‘universal health and proactive health’ into the formulation and implementation of various government policies. This represents a systemic arrangement by the state to better safeguard public health in the current and forthcoming periods. With the advent of the post-pandemic era, people will pay greater attention to personal and family health protection, becoming more conscious and proactive in seeking and acquiring new health knowledge, technologies, and services. Hereby, I also call on my peers in the pharmaceutical and medical industries to seize the new values and concepts centered on ‘patients’ and ‘public health,’ as well as the strategic opportunities presented by national policy, to expand earlier and more extensively from the traditional domain of ‘treatment’ into the broader blue ocean of ‘prevention.’ Let us join forces to contribute to the realization of the visionary goals of ‘Healthy China 2030,’” added Ouyang Jianxiang.

Regarding future plans, Cheng Yilang told VCBeat that, as a health service platform enterprise, Yikang Jucheng will primarily serve as a connector and technology enabler.“We sincerely welcome peers in the pharmaceutical and medical device industries, as well as enterprises related to health management services, to join the Yikang Jucheng Health Service Platform, working together to make a meaningful impact for patients with diabetes and other chronic diseases, as well as individuals in a sub-health state.”